Intracranial mesenchymal tumor with FET‐CREB fusion—A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma‐like neoplasms
Top Cited Papers
Open Access
- 3 November 2020
- journal article
- research article
- Published by Wiley in Brain Pathology
- Vol. 31 (4) , e12918
Abstract
Intracranial mesenchymal tumors with FET‐CREB fusions are a recently described group of neoplasms in children and young adults characterized by fusion of a FET family gene (usually EWSR1, but rarely FUS) to a CREB family transcription factor (ATF1, CREB1, or CREM), and have been variously termed intracranial angiomatoid fibrous histiocytoma or intracranial myxoid mesenchymal tumor. The clinical outcomes, histologic features, and genomic landscape are not well defined. Here, we studied 20 patients with intracranial mesenchymal tumors proven to harbor FET‐CREB fusion by next‐generation sequencing (NGS). The 16 female and four male patients had a median age of 14 years (range 4–70). Tumors were uniformly extra‐axial or intraventricular and located at the cerebral convexities (n = 7), falx (2), lateral ventricles (4), tentorium (2), cerebellopontine angle (4), and spinal cord (1). NGS demonstrated that eight tumors harbored EWSR1‐ATF1 fusion, seven had EWSR1‐CREB1, four had EWSR1‐CREM, and one had FUS‐CREM. Tumors were uniformly well circumscribed and typically contrast enhancing with solid and cystic growth. Tumors with EWSR1‐CREB1 fusions more often featured stellate/spindle cell morphology, mucin‐rich stroma, and hemangioma‐like vasculature compared to tumors with EWSR1‐ATF1 fusions that most often featured sheets of epithelioid cells with mucin‐poor collagenous stroma. These tumors demonstrated polyphenotypic immunoprofiles with frequent positivity for desmin, EMA, CD99, MUC4, and synaptophysin, but absence of SSTR2A, myogenin, and HMB45 expression. There was a propensity for local recurrence with a median progression‐free survival of 12 months and a median overall survival of greater than 60 months, with three patients succumbing to disease (all with EWSR1‐ATF1 fusions). In combination with prior case series, this study provides further insight into intracranial mesenchymal tumors with FET‐CREB fusion, which represent a distinct group of CNS tumors encompassing both intracranial myxoid mesenchymal tumor and angiomatoid fibrous histiocytoma‐like neoplasms.Keywords
Funding Information
- NIH Office of the Director (DP5 OD021403)
This publication has 38 references indexed in Scilit:
- Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 proteinActa Neuropathologica, 2013
- Tumors With EWSR1-CREB1 and EWSR1-ATF1 FusionsAmerican Journal of Surgical Pathology, 2012
- Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 FusionAmerican Journal of Surgical Pathology, 2011
- EWSR1‐ATF1 fusion is a novel and consistent finding in hyalinizing clear‐cell carcinoma of salivary glandGenes, Chromosomes and Cancer, 2011
- Angiomatoid fibrous histiocytoma: unusual sites and unusual morphologyLaboratory Investigation, 2011
- Primary Intracerebral Angiomatoid Fibrous HistiocytomaAmerican Journal of Surgical Pathology, 2008
- EWSR1‐CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytomaGenes, Chromosomes and Cancer, 2007
- EWS-CREB1: A Recurrent Variant Fusion in Clear Cell Sarcoma—Association with Gastrointestinal Location and Absence of Melanocytic DifferentiationClinical Cancer Research, 2006
- Clear cell sarcoma of tendons and aponeuroses in pediatric patientsCancer, 2002
- Molecular Diagnosis of Clear Cell SarcomaThe Journal of Molecular Diagnostics, 2002